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A panel of human hematopoietic cell lines was genetically engineered to express recombinant complement receptor 2
(CR2 or CD21), which is also the Epstein–Barr virus (EBV) receptor. The panel was composed of SupT1, J1.1, and U1.HIV
cells. The latter is a promonocytic cell line, whereas the other two are T lymphocytic cell lines. J1.1 and U1.HIV cells are
latently infected by human immunodeficiency virus type 1 (HIV-1). These three cell lines were transduced with a murine
leukemia virus (MLV)-based retroviral vector system. CR2 was efficiently and consistently expressed on the cell membranes,
conferring enhanced susceptibility to EBV infection. The efficient expression of recombinant CR2 in cell lines of hematopoietic
origin allowed for study of the interaction between EBV infection and HIV-1 gene regulation in suitable cell-culture models.
The effects of EBV and HIV-1 coinfection results were cell-type dependent. In the two T lymphocytic cell lines, HIV-1
expression was rapidly and persistently down-regulated by EBV. Conversely, in the promonocytic cell line U1.HIV-CR2, HIV-
1 expression was transiently enhanced by EBV. The EBV and HIV-1 coinfection result in U1.HIV-CR2 cells is potentially
important, as the activation of HIV-1 gene expression in monocyte-like cells may play a crucial role in the mechanism of
CD4/ T cell depletion by apoptosis. Therefore, the U1.HIV-CR2 cell line may represent a useful cell-culture system to study
the synergism between EBV and HIV-1 in inducing apoptosis in primary CD4/ T cells. q 1997 Academic Press
INTRODUCTION gism between EBV and HIV-1 in the lymphomagenesis
process. The EBV receptor is CR2, which is primarily
Epstein–Barr virus (EBV) is a ubiquitous human her-
expressed on B lymphocytes (Iida et al., 1983; Weis et
pes virus. Normally, it causes a mild illness in children
al., 1984; Ross et al., 1973; Tedder et al., 1984). How-
and then becomes latent. Infected individuals are asymp-
ever, EBV cell tropism is not exclusively restricted to
tomatic lifelong carriers. The biology of EBV infection has
B cells, as it can also infect epithelial cells (Sixbey et
been extensively investigated because of its association
al., 1984; Greenspan et al., 1985) and, more rarely, T
with B cell lymphoma and enhanced pathogenicity in
lymphoma cells (Jones et al., 1988). The mechanism of
immunocompromised individuals. A particular emphasis
EBV infection of epithelial and T lymphoma cells has
has been dedicated to AIDS, malaria, and transplant pa-
not been established.
tients who have received immunosuppressive therapy.
In order to determine the events that are involved in
In all these individuals, EBV is associated with various
the activation of HIV-1 replication and in the EBV patho-
lethal neoplasias, among which are B cell (Levine, 1993)
genesis in patients with AIDS, it is essential to character-
and rare T cell lymphomas (Jones et al., 1988; Su et al.,
ize at the molecular level the interaction between the
1993; Ott et al., 1992), Hodgkin’s disease (Weiss et al.,
two viruses in a relevant cell culture model. For this
1989), nasopharyngeal carcinoma (Desgranges et al.,
purpose, we have genetically engineered a panel of
1975; Raab-Traub et al., 1987), and possibly cervical car-
CD4/ hematopoietic cell lines to express recombinant
cinoma (Landers et al., 1993).
CR2 onto their surface.
The impairment of the immune system may involve
In addition, the emergence of AIDS-related, EBV-asso-
the depletion of EBV-specific cytotoxic T lymphocytes.
ciated T cell lymphomas as a distinct clinical pathological
This phenomenon greatly contributes to the develop-
entity underscores the importance of EBV infection of T
ment of EBV-related pathogenesis, but it is unlikely to
cells. Several reports have shown that EBV infects T cell
be the unique initiating event in AIDS patients. Many lines (Fischer et al., 1991; Sinha et al., 1993; Hedrick
aspects of the human immunodeficiency virus type 1 et al., 1994), although they express low levels of CR2
(HIV-1)-induced lymphomagenesis mechanism(s) have (Fingeroth et al., 1984). The ability to study EBV infection
not been properly defined. Most likely, there is a syner- of T cells is limited by the low levels of CR2 expression
that causes an inefficient infection by EBV. The availabil-
ity of T cell lines expressing high levels of CR2 and which1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (215) 707-7788. are efficiently infected by EBV would greatly advance
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the study of the pathobiology of EBV-associated T cell incubated with the FITC-conjugated antibody to CR2 (B2)
for 30 min on ice. The FITC-conjugated monoclonal anti-lymphomas.
body to CR2 was purchased from Biosource International
(Camarillo, CA) and used at a dilution of 1:30 in PBSMATERIALS AND METHODS
supplemented with 1% BSA. Cells were then washed
Plasmids three times with FACS buffer, resuspended with 1 ml of
FACS buffer, and analyzed using a Coulter Epics ProfilepHIT60 and pHIT456 were kindly provided by Dr. Alan
II equipped with an autocloning attachment.Kingsman (University of Oxford, UK) and are described
elsewhere (Soneoka et al., 1995). pHIT60 contains the
DNA-PCRmurine leukemia virus (MLV) gag/pol cassette under the
control of the hCMV immediate early promoter, whereas Genomic DNA was extracted from 2 1 107 cells with
pHIT456 contains the CMV driven MLV amphotropic en- a DNA purification kit (Blood and Cell DNA Maxi kit,
velope. Both plasmids carry the SV40 origin of replication Qiagen, Chatsworth, CA), following manufacturer’s in-
in their backbone. structions. PCR analysis of EBV DNA EBNA-2A was car-
pZip-NeoSV(X)1-CR2 was a gift of Dr. Fred Wang (Har- ried out with 10 mg of genomic DNA as described (Sam-
vard Medical School) and is described by Li et al. (1992). ple et al., 1990). The upstream primer was 5* GCAGGG-
In this plasmid, CR2 cDNA was inserted into the expres- ATGCCTGGACACAA 3* (Sample et al., 1990) [positions
sion vector pZip-NeoSV(X)1 (Cepko et al., 1984), which 1813 to 1832, genome coordinates are given with refer-
contains the neomycin resistance gene. The MLV long- ence to the B95.8 genome’s sequence of Katsuki et al.
terminal repeat (LTR) drives the CR2 expression and gen- (1979)]. The downstream primer was 5* TTGTGACAG-
erates an RNA transcript that is also substrate for pack- AGGTGACAAAA 3* (Sample et al., 1990) [positions 2042
aging into the MLV virion, for reverse transcription, and to 2061 (Katsuki et al., 1979)].
for integration into the host cell genome. Amplification products were separated in a 1.4% aga-
rose gel and visualized by ethidium bromide staining.
Cell lines, viral strains, transfections, and viral
transductions Reverse transcriptase (RT)-PCR
SupT1, Raji, and BJAB cell lines were purchased from Total cellular RNA was extracted from 5 1 106 cells
ATCC. J1.1 and U1.HIV cell lines were obtained from the with an RNA purification kit (RNeasy Total RNA kit, Qia-
AIDS Research Reagent Program (Rockville, MD). B95.8 gen), following manufacturer’s instructions. cDNA was
cell line was a gift of Dr. George Miller (Yale University). synthesized from 50 ml of the total RNA (5 1 106 cells)
All the above-mentioned cell lines were grown in RPMI- with a cDNA synthesis kit (3* race for rapid amplification
1640 supplemented with 10% fetal bovine serum and 2 of cDNA ends, Gibco BRL, Gaithersburg, MD). The cDNA
mM L-glutamine. Transduced SupT1-CR2, J1.1-CR2, and preparation was divided into aliquots. For BZLF1 RT-PCR
U1.HIV-CR2 cell lines were grown in RPMI-1640 supple- analysis was carried out as described (Paterson et al.,
mented with 10% fetal bovine serum, 2 mM L-glutamine 1995). The upstream primer was 5* AGGTGCCTTTTG-
and 1 mg/ml G418. The fetal human kidney carcinoma TACAAGCT 3* (Paterson et al., 1995) [positions 103081
293T cell line was produced in Dr. David Baltimore’s to 103100 (Katsuki et al., 1979)], and the downstream
laboratory (Pear et al., 1993) and was purchased from primer was 5* ATAATGGAGTCAACATCCAG 3* (Paterson
ATCC upon authorization of Rockefeller University. 293T et al., 1995) [positions 102256 to 102275 (Katsuki et al.,
cells were grown in DMEM supplemented with 10% fetal 1979)]. For b-actin RT-PCR analysis (Titti et al., 1992), the
bovine serum and 2 mM L-glutamine. upstream primer was 5* ATCAAGATCATTGCTCCTCCT
HIV-1 IIIB was obtained from the AIDS Research Re- 3* (Titti et al., 1992) [positions 1019 to 1040 (Titti et al.,
agent Program and used for viral infections as described 1992)], and the downstream primer was 5* AACTGGAAC-
elsewhere (Henderson et al., 1991). EBV was extracted GGTGAAGG 3* (Titti et al., 1992) [positions 1137 to 1154
from B95.8 cell line and used for viral infection as de- (Titti et al., 1992)]. For BRLF1 RT-PCR analysis (Paterson
scribed previously (Henderson et al., 1991). et al., 1995), the upstream primer was 5* AGGCCTAAA-
Transient calcium phosphate DNA transfections of AAGGATGGCTT 3* (Paterson et al., 1995) [positions
293T cells were carried out as described (Pear et al., 105180 to 105161 (Katsuki et al., 1979)], and the down-
1993). MLV retroviral vectors were harvested and utilized stream primer was 5* ACCAATGTCTGCTAGCTGTT 3*
for transducing target cells as described by Soneoka et (Paterson et al., 1995) [positions 102721 to 102740 (Kat-
al. (1995). suki et al., 1979)]. For EBER1 RT-PCR analysis (Tierney
et al., 1994), the upstream primer was 5* AAAACATGC-Flow cytometric analysis
GGACCACCAGC 3* (Tierney et al., 1994) [positions 6776
to 6795 (Katsuki et al., 1979)], and the downstream primerCells (1 1 106) were washed three times with FACS
buffer [phosphate-buffered saline (PBS) containing 1% was 5* AGGACCTACGCTGCCCTAGA 3* (Tierney et al.,
1994) [positions 6648 to 6629 (Katsuki et al., 1979)].bovine serum albumun (BSA) and 0.1% sodium azide],
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pHIT456 expresses the MLV amphotropic envelope.Amplification products were analyzed by electrophore-
These two plasmids generate RNA transcripts which aresis through a 1.4% agarose gel and stained with ethidium
substrate only for translation in 293T-transfected cells,bromide.
as the MLV LTRs have been replaced by the CMV pro-
Detection of VCA and EBNA in EBV-infected cells by moter, and the packaging signal has been deleted. For
IFA and ACIF these reasons, the retrovirus which is produced is not
competent for replication and can sustain only one round
PBL and CR2-expressing cell lines were infected by of infection. pHIT60 and pHIT456 carry the SV40 origin
EBV as described (Henderson et al., 1991). Cells were of replication in their backbone; therefore, the large T
washed three times with PBS at a concentration of 1 1 antigen will produce high DNA plasmid copy number
106 cells per milliliter, and 50 ml of cell suspension was after cotransfection in 293T cells. The retroviral vector
seeded in multiwell slides and let dry at room tempera- that was cotransfected with the MLV-packaging compo-
ture. Cells were fixed with acetone for 20 min. Slides nents was pZip-NeoSV(X)1-CR2 (Li et al., 1992). This plas-
either were used or were stored at 0207. mid contains the MLV LTR driven CR2 cassette and the
Human sera, positive for EBV, were heated at 567 for neomycin resistance gene. The RNA genome encoded
30 min to inactivate the complement. The sera were di- in the pZip-NeoSV(X)1-CR2 is substrate for packaging
luted 1:10 with PBS to detect EBV viral capsid antigen into the virion, since it contains the packaging signal
(VCA) and EBV-associated nuclear antigen (EBNA) in cell (C/), for reverse transcription, and will integrate into the
lines infected by EBV. Fifty microliters of diluted human host genome, since it contains the MLV LTRs. Virus ex-
sera was added to the wells containing the fixed cells traction and infection of target cells were carried out as
and incubated for 45 min at 377. Slides were then washed described (Soneoka et al., 1995). The amount of target
three times with PBS. cells was increased to 5 1 106, in order to have a signifi-
The EBV VCA was detected by indirect immunofluores- cant amount of transduced cells after G418 selection,
cence assay (IFA). The secondary antibody was an FITC- which was carried out at a concentration of 1 mg/ml, in
conjugated goat anti-human polyclonal antibody (Pierce, RPMI-1640 (Sigma), supplemented with 10% fetal bovine
Rockford, IL). It was diluted 1:40 with PBS, and 50 ml was serum (Gibco), and 2 mM L-glutamine (Gibco). Mock con-
added to each well. Slides were incubated for 45 min at trol untransduced SupT1, J1.1, and U1.HIV cells died after
1 week of drug selection.377, washed three times with PBS, and analyzed under
UV light with an Olympus microscope. CR2 expression on target cells
The EBV EBNA was detected by anticomplement im-
CR2 expression in transduced J1.1, U1.HIV, and SupT1
munofluorescence assay (ACIF) as described elsewhere
cell lines was readily detected by FACS analysis (Fig. 1).
(Reedman et al., 1973). Guinea pig complement and Values are listed in Table 1. The levels of CR2 expression
FITC-conjugated goat anti-guinea pig complement poly- in J1.1-CR2 and SupT1-CR2 cell lines were comparable
clonal antibodies were purchased from Cappel (West to those of the B-lymphocytic cell line Raji (Fig. 1). The
Chester, PA). parent cell lines J1.1 and SupT1 did not show a significant
amount of CR2-like molecule expression, which could be
RT Assay
identified by the monoclonal antibody used in this assay
(Fig. 1). The signal increase of J1.1-CR2 cells was 40-The accumulation of HIV-1 RT activity in cell culture
fold over that of J1.1 cells, whereas the signal increasesupernatants was measured as described previously
of SupT1-CR2 cells was in the range of 6-fold over that(Henderson et al., 1991).
of SupT1 cells. The basal level of CR2-like molecule in
U1.HIV cells was almost as high as the CR2 expressionRESULTS
level of Raji cells. After viral transduction, U1.HIV-CR2
Transduction of target cell lines with CR2 expression cells expressed a CR2-associated signal which was al-
vector most double that of Raji and U1.HIV cell lines.
The three CR2-transduced cell lines J1.1-CR2, U1.HIV-SupT1, J1.1, and U1.HIV cell lines were transduced
CR2, and SupT1-CR2 were continuously cultured in com-with an MLV-based retroviral vector system (Soneoka et
plete RPMI-1640 supplemented with G418 at a concen-al., 1995), with the goal of expressing recombinant CR2
tration of 1 mg/ml. The presence of G418 did not seemon their surface. This retroviral vector system allows for
to affect cell growth and is essential to maintain CR2rapid production of high-titer retroviral stocks following
expression (data not shown). After a long-term culture,transient transfection of 293T cells (Pear et al., 1993),
the levels of CR2 expression did not change under drug-which are highly transfectable and contain the SV40 large
selection conditions.T antigen. The MLV components, gag/pol and ampho-
Detection of EBV DNA in CR2-expressing cell linestropic envelope, are placed on two different plasmids to
after EBV infectionavoid replication-competent virus formation (Markowitz
et al., 1988), and both are under the control of the hCMVie To determine whether the CR2 expressed on trans-
duced cell lines was biologically active, we tested theirpromoter. pHIT60 expresses MLV gag/pol, whereas
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FIG. 1. Flow cytometric analysis of CR2 (CD21) expression in the panel of cell lines, before and after cell transduction with the MLV retroviral
vector. The assay was carried out as described under Materials and Methods.
susceptibility to EBV (strain B95.8) infection. Following attached to the surface of the target cell. Therefore, to
confirm whether EBV infects the CR2-expressing cells,exposure to EBV (m.o.i. approximately 1), DNA-PCR anal-
ysis of EBV EBNA-2A DNA sequences (Fig. 2) showed a we also examined for viral mRNA transcripts.
The target cells were challenged with EBV for 72 hr.positive signal in J1.1-CR2, U1.HIV-CR2, SupT1-CR2, and
B95.8 cell lines. Interestingly, U1.HIV was negative by The total RNA was extracted as described (Materials
and Methods). The mRNA analyzed by RT-PCR includedDNA-PCR analysis, despite the high levels of CR2-like
molecule expression (Fig. 1). BZLF1 (Fig. 3A, upper panel), BRLF1 (Fig. 3B), and EBER1
(Fig. 3C). The quality and the quantity of the mRNA among
the various samples shown in the RT-PCR assays wereEBV-encoded transcripts BZLF1, BRLF1, and EBER1 in
CR2-expressing cell lines assessed by comparison with b-actin mRNA (Fig. 3A,
lower panel). Only the CR2-expressing cell lines J1.1-
The presence of EBV DNA following exposure of J1.1- CR2, U1.HIV-CR2, and SupT1-CR2, and the B-lymphoid
CR2, U1.HIV-CR2, and SupT1-CR2 cell lines to EBV sug- cell line B95.8 were positive by RT-PCR analysis of EBV
gests that the transduced CR2 molecule is biologically encoding BZLF1, BRLF1, and EBER1 transcripts (Figs.
active, as it can serve as an EBV receptor, and it confers 3A, upper panel, 3B and 3C). The primers used for RT-
susceptibility to EBV infection. However, the DNA in PCR PCR analysis of BZLF1 and BRLF1 were specific for
analysis signal could be generated by EBV DNA in virions mRNA (Paterson et al., 1995). If there would have been
an EBV DNA contamination, the primers for BZLF1 would
have produced a PCR fragment of 844 bp instead of 634TABLE 1
Flow Cytometric Analysis of CR2 (CD21) Expression
CR2 (CD21)
Cell line Percentage a SD b
J1.1 1.1 0.5
J1.1-CR2 42.5 3.6
U1 47.9 0.5
U1-CR2 99.5 3.5
SupT1 5.1 0.7
SupT1-CR2 31.7 0.7
CD4/ T cells 9.4 2.9 FIG. 2. DNA-PCR analysis of EBNA-2A. The molecular size marker
is indicated to the right of the panel. Genomic cellular DNA was ex-Raji 54.2 1.6
tracted and analyzed by PCR as described under Materials and Meth-
ods. Amplification products were separated in a 1.4% agarose gel anda Percentage of CR2 (CD21) expression on the cells.
b Standard deviation of fluorescence intensity. stained with ethidium bromide.
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FIG. 3. Analysis of transcription program by RT-PCR. (A) BZLF1 and b-actin mRNA expression as detected by RT-PCR. BZLF1 mRNA is shown
in the upper panel, whereas b-actin mRNA is shown in the lower panel. (B) BRLF1 RT-PCR. (C) EBER1 RT-PCR. The molecular size markers are
indicated to the right of each panel. Total cellular RNA extraction, reverse transcription and cDNA PCR amplification were carried out as described
under Materials and Methods. Amplification products were separated in a 1.4% agarose gel and stained with ethidium bromide.
bp (Fig. 3A, upper panel), whereas the primers for BRLF1 infection has given a different figure. Overall, J1.1-CR2,
U1.HIV-CR2, and SupT1-CR2 cell lines preferentially ex-would have given a PCR fragment of 2459 bp instead of
472 bp (Fig. 3B). press EBNA rather than VCA (Table 2). The expression
levels of EBV EBNA were 80.0% in J1.1-CR2 cell line,
Detection of EBV VCA and EBNA in EBV-infected 50.0% in U1.HIV-CR2 cell line, and 35.0% in SupT1-CR2.
cells The latter cell line scored an expression level of EBV
EBNA which was comparable to that of EBV-infected PBLIn order to establish the efficiency of EBV infection in
cells. In Fig. 4, representative results showing the local-our cell culture systems, the expression of EBV VCA and
ization of the fluorescence signal in cells analyzed forEBNA was determined by IFA and by ACIF (Reedman et
EBV VCA and EBNA expression are reported. As ex-al., 1973), respectively. Results are summarized in Table
pected, the fluorescence for VCA is localized in the cell2. The expression levels of EBV VCA in U1.HIV-CR2 cell
membrane (Fig. 4; J1.1-CR2, U1.HIV-CR2, SupT1-CR2, andline seem comparable to those of EBV-infected PBL cells
PBL cells). Conversely, for EBV EBNA detection, the fluo-(27.0 vs 29.0%). The percentage of EBV VCA-positive J1.1-
rescence signal is mainly localized in the cell nucleusCR2 and SupT1-CR2 cells was slightly lower than that of
(Fig. 4; J1.1-CR2, U1.HIV-CR2, SupT1-CR2, and PBL cells).EBV-infected PBLs (23.0 and 20.0% for J1.1-CR2 and
SupT1-CR2, respectively, over 29.0% of VCA-positive PBL Effects of EBV on HIV-1 expression in latently
cells). The analysis of EBV EBNA expression post-EBV infected T lymphocytic and promonocytic cell lines
A number of EBV-encoded gene products have been
TABLE 2 shown to interact with the HIV-1 LTR in cotransfection
assays (Lin, 1993; Quinlivan et al., 1990). Therefore, theDetection of EBV VCA and EBNA by IFA and ACIF
effects of EBV infection on HIV-1 expression were exam-
VCA EBNA ined in our model system. The effects of EBV on HIV-1
Cell line percentage a percentage a gene regulation were studied by RT assay in time-course
experiments on J1.1 and J1.1-CR2 (Fig. 5A), U1.HIV, andJ1.1/EBV 2.5 3.1
U1.HIV-CR2 (Fig. 5B). In CR2-transduced T lymphocyticJ1.1-CR2/EBV 23.0 80.0
U1/EBV 0.8 1.9 cells J1.1-CR2, HIV-1 gene expression was rapidly and
U1-CR2/EBV 27.0 50.0 persistently down-regulated by EBV (Fig. 5A). The down-
SupT1/EBV 2.4 2.3 regulation of RT activity was in the range of 3- or 4-
SupT1-CR2/EBV 20.0 35.0
fold. Conversely, in CR2-transduced promonocytic cellsPBL/EBV 29.0 31.5
U1.HIV-CR2, HIV-1 gene expression was readily and only
a Percentage of positive cells expressing EBV antigens. transiently enhanced by EBV infection (Fig. 5B). The RT
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activity in SupT1-CR2 cells, independently from the order
of coinfection (Fig. 6). The decrease was in the range of
3-fold. High levels of RT activity in HIV-1-infected SupT1
cells were unaffected by EBV coinfection (Fig. 6).
UV-irradiated EBV does not affect HIV-1 gene
expression
In order to establish whether the effects observed on
HIV-1 gene expression in our cell culture systems were
specific to EBV infection, rather than a simple ligation of
CR2 molecule, J1.1-CR2-, U1.HIV-CR2-, and HIV-1-in-
fected SupT1-CR2 cells were challenged with EBV and
with UV-irradiated EBV. Supernatants from J1.1-CR2 and
U1.HIV-CR2 cells were harvested 4 hr post-EBV infection
and tested by RT assay to measure HIV-1 gene expres-
sion. As reported in Fig. 7A, UV-irradiated EBV did not
down-regulate HIV-1 gene expression in J1.1-CR2 cells
and did not increase RT activity in U1.HIV-CR2 cells.
Levels of RT activity in the supernatants of J1.1-CR2 cells
did not change 48 hr post-EBV and UV-irradiated EBV
treatment, whereas RT activity was at background level
in the supernatant of U1.HIV-CR2 treated with EBV and
UV-irradiated EBV (data not shown). Also, Fig. 7B shows
a lack of HIV-1 down-regulation by UV-irradiated EBV in
HIV-1-infected SupT1-CR2 cells. The various superna-
tants were harvested from SupT1-CR2 cells 72 hr postvi-
FIG. 4. Detection of EBV VCA and EBNA by IFA and ACIF, respec- ral infections.
tively. CR2-expressing cell lines were infected with EBV B95.8 for 3
days and VCA and EBNA expression was analyzed as described under
ConclusionMaterials and Methods. The arrows depict fluorescence localization
among the various cell lines.
In summary, EBV infection showed both a CR2-specific
and a cell-type-dependent pattern on HIV-1 gene regula-
tion. In CR2-expressing T lymphocytic J1.1-CR2 and HIV-activity increase was about 10-fold after 4 hr treatment,
1-infected SupT1-CR2 cell lines, HIV-1 gene expressionand only 2-fold 24 hr post-EBV infection. The RT activity
was rapidly and persistently down-regulated by EBVin the supernatant of J1.1 and J1.1-CR2 cell lines was
(Figs. 5A and 6, respectively), whereas, in the CR2-ex-constitutively high (Fig. 5A). RT activity in the supernatant
pressing promonocytic U1.HIV-CR2 cell line, HIV-1 geneof J1.1-CR2 cells at t  0 hr was half of that in the super-
expression was transiently enhanced by EBV infectionnatant of J1.1 cells. The addition of TNF-a increased RT
(Fig. 5B). The fact that UV-irradiated EBV does not displayactivity in supernatant of J1.1-CR2 cells to the same ex-
any effect on HIV-1 gene regulation in J1.1-CR2, U1.HIV-tent as in J1.1 cells.
CR2, or HIV-1-infected SupT1-CR2 cell lines (Fig. 7A andThe basal levels of RT activity in the supernatants of
7B) indicates that the ligation of recombinant CR2 is notU1.HIV and U1.HIV-CR2 cells were constitutively low (Fig.
affecting HIV-1 gene expression.5B). The addition of TNF-a had a remarkable effect on
U1.HIV RT activity (about 250-fold) (Fig. 5B), whereas
U1.HIV-CR2 cells responded to a lesser extent (about 3- DISCUSSION
fold) (Fig. 5B).
The recent emergence of AIDS-related, EBV-associ-
ated T cell lymphomas underscores the biological signifi-Effect of EBV on HIV-1 gene expression in a CR2-
cance of EBV infection of T cells. The availability of Ttransduced T cell line
lymphocytic and promonocytic cell lines expressing high
levels of the B cell-derived EBV receptor CR2 will allowFrom the results just described, it is apparent that
EBV infection of cell lines expressing CR2 and latently for better study of the etiology and biology of EBV- and
HIV-1-associated T cell lymphomas. In pursuit of theseinfected with HIV-1 altered HIV-1 gene expression. To
determine whether EBV infection could also alter acute goals, the MLV-based retroviral vector system described
by Soneoka et al. (1995) and the CR2 expression systemHIV-1 infection, the T lymphocytic cell line SupT1-CR2
was coinfected with EBV (strain B95.8) and HIV-1. The described by Li et al. (1992) greatly facilitated our study.
The method described by Soneoka et al. (1995) is basedcoinfection of EBV with HIV-1 caused a decrease of RT
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FIG. 5. RT assay of supernatants harvested from J1.1, J1.1-CR2, U1.HIV, and U1.HIV-CR2, after EBV infection or TNF-a treatment. J1.1 and J1.1-
CR2 are reported in A, whereas U1.HIV and U1.HIV-CR2 are reported in B. RT assay counts are indicated to the left of each panel. RT assay was
carried out as described previously (Henderson et al., 1991). The various supernatants were tested by RT assay after EBV infection at different
times: t  0, 4, 24, 48, and 72 hr. As positive control, J1.1, J1.1-CR2, U1.HIV, and U1.HIV-CR2 were treated with TNF-a at 20 U/ml for 72 hr. The
EBV-infected cells were used for total RNA extraction, which was analyzed by RT-PCR to confirm the presence of EBV in the CR2-transduced cell
lines and its absence in the parental cell lines (data not shown).
on an overexpression system that allows for rapid pro- by the quantification of expression levels of EBV VCA
and EBNA, carried out by IFA and ACIF analysis (Tableduction of high-titer retroviral stocks, which is the most
critical requirement for efficient cell transduction. For this 2 and Fig. 4). These findings parallel previous studies on
human epithelial cells (Li et al., 1992), human erythroleu-reason, it was possible to achieve a stable and efficient
expression of CR2 in CD4/ hematopoietic cell lines, kemic K562 cell line (Carel et al., 1989), and murine fibro-
blast L cell line (Ahearn et al., 1988). EBV did not infectwhich are normally refractory to retroviral transduction
(von Kalle et al., 1994) and to DNA transfection (Hofmann parental J1.1, U1.HIV, and SupT1 cell lines (Figs. 2 and
3A–3C). Interestingly, U1.HIV cells express high levelset al., 1996). Various transfection techniques are currently
available to introduce DNA into cells. However, they are of CR2-like molecule (Fig. 1). This finding suggests that
EBV in vitro infection of CD4/ hematopoietic cell linesall highly dependent on the degree of transfectability of
the target cells (Corsaro and Pearson, 1981a,b; Gorman may only occur at high multiplicities of viral infection,
since the EBV binding to the CR2-like molecule may oc-et al., 1993) and do not always allow for stable gene
expression. CR2 expression has been efficiently cur with low specificity or because the CR2-like molecule
on T lymphocytic and promonocytic cells is for someachieved by DNA transfection of human epithelial cells
(Li et al., 1992), human erythroleukemic K562 cell line reason not fully biologically functional. For instance, a T
lymphocytic cell line, Molt-4, is not infected by EBV, al-(Carel et al., 1989), and a murine fibroblast L cell line
(Ahearn et al., 1988). These cell-culture models have though it expresses minimal levels of CR2-like molecule,
to which EBV binds (Fingeroth et al., 1984). A similarbeen useful in studying EBV binding to CR2, the viral
growth cycle in epithelial cells, and EBV-transforming finding was also observed in promyelocytic HL-60 and
promonocytic U937 cell lines (Gosselin et al., 1991). U937properties in cell lines different from B lymphocytes. The
analysis of EBV infection in T lymphomas and in HIV-1- is the parental cell line of U1.HIV. A CR2-like molecule
was detected in HL-60 and U937 cell lines. EBV couldinfected hematopoietic cells has been hampered by the
lack of a proper cell-culture system. Some T cells express bind to this molecule, but failed to infect HL-60 and U937
cells (Gosselin et al., 1991). The lack of EBV infection oflow levels of a CR2-like molecule (Fischer et al., 1991;
Hedrick et al., 1994) and are to a low extent susceptible U937 cells parallels our finding observed for U1.HIV cell
line (Figs. 2 and 3A–3C). Interestingly, in another studyto EBV infection. The cell lines we have genetically engi-
neered (J1.1-CR2, U1.HIV-CR2, and SupT1-CR2) express (Revoltella et al., 1989), EBV DNA was detected in precur-
sor monocyte-macrophage cell lines, established fromhigh levels of CR2 (Fig. 1) and are readily infectable by
EBV, as shown by DNA PCR analysis (Fig. 2), by RT-PCR bone marrow of children suffering from maturation de-
fects of hematopoiesis. Therefore, EBV may infect precur-analysis of EBV-encoded transcripts (Figs. 3A–3C), and
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In our cell-culture models, EBV displayed a differen-
tial pattern on HIV-1 gene regulation, which was cell-
type-dependent. In CR2-transduced T lymphocytic cell
lines (J1.1-CR2 and SupT1-CR2), HIV-1 gene expression
was rapidly and persistently down-regulated by EBV
(Figs. 5A and 6). This result parallels that of a previous
study (Henderson et al., 1991), in which HIV-1 expres-
sion was down-regulated by B95.8 EBV strain in primary
B cells. In the CR2-transduced promonocytic cell line
(U1.HIV-CR2), HIV-1 expression was rapidly and tran-
siently activated by EBV (Fig. 5B). These findings were
not related to the ligation of recombinant CR2, as UV-
irradiated EBV had no effect on HIV-1 gene regulation
in these cell lines (Figs. 7A and 7B). Therefore, infec-
tious EBV is required to affect HIV-1 gene regulation.
The immediate response of HIV-1 regulation to EBV
infection in all the cell lines we have examined was
surprising. Interestingly, EBV infection had no effect on
CD4 or on fusin expression in our cell-culture systems
(data not shown). Most likely, the EBV factor(s) involved
in HIV-1 gene regulation is already functional immedi-FIG. 6. RT assay of supernatants harvested from SupT1 and SupT1-
ately after EBV entry in the cell, and might act in concertCR2 cells (0.5 1 106 cells per point), after viral infections with HIV-1
and/or EBV. SupT1 and SupT1-CR2 cells were incubated with EBV and/ with other cellular factors. Good candidates for this
or HIV-1 as described (Henderson et al., 1991), at different time points. effect are EBV-encoded immediate-early transactiva-
At the end of the incubation time, cells were washed and kept in culture tors. Another possibility is the stimulation of host cyto-
for 72 hr, in 5 ml of RPMI-1640 supplemented with 10% fetal bovine
kines post-EBV infection, which display a regulatoryserum and 2 mM L-glutamine. Supernatants were then tested in RT
effect on HIV-1 gene expression. Furthermore, EBV it-assay to quantify the amount of HIV-1 RT as described previously
(Henderson et al., 1991). EBV infection efficiency of SupT1-CR2 cells self encodes a gene, BCRF1, which is homolog to hu-
was assessed by RT-PCR of total RNA extracted from cell lysates (data man IL-10, and shares many of cellular cytokine’s bio-
not shown). RT assay counts are indicated to the left of the panel. The logical functions (Moore et al., 1993; Ho and Moore,
various time points are indicated at the bottom of the graph, for SupT1
1994). High levels of IL-10 expression can suppressand SupT1-CR2: medium; EBV by its own for 72 hr; HIV-1 by its own
HIV-1 replication (Weissman et al., 1994). Paradoxically,for 72 hr; EBV and HIV-1 added simultaneously for 72 hr; HIV-1 added
24 hr before EBV (72 hr treatment for HIV-1 and 48 hr treatment for lower doses of IL-10 enhance HIV-1 replication in cells
EBV); EBV added 24 hr before HIV-1 (72 hr treatment for EBV and 48 of monocytic lineage (Weissman et al., 1995). This
hr treatment for HIV-1); HIV-1 by its own for 48 hr. could explain why EBV displayed a cell-type-dependent
pattern on HIV-1 gene regulation in T lymphocytic and
promonocytic cell lines and why the activation of HIV-sor monocyte cells, under certain circumstances (Revol-
tella et al., 1989). 1 was transient in promonocytic U1.HIV-CR2 cells post-
EBV infection. The activation of HIV-1 gene expressionIn this report, the effects of EBV on HIV-1 gene regula-
tion have been analyzed in T lymphocytic and promono- in cells of monocytic lineage may play a crucial role in
the pathogenesis of AIDS (Meltzer et al., 1990). It hascytic cell lines, which have been genetically engineered
to express recombinant B cell-derived CR2. SupT1-CR2 been reported that the expression of HIV-1 envelope in
monocytes can prime in vitro CD4/ T cells for apoptosisand J1.1-CR2 are human T lymphocytic cell lines. U1.HIV-
CR2 is a human promonocytic cell line. J1.1-CR2 and (Cottrez et al., 1997). This finding may be one of the
key factors involved in the mechanism of CD4/ T cellU1.HIV-CR2 are latently infected by HIV-1 and therefore
might be useful cell culture models in which to study the depletion in patients with AIDS. In this respect, EBV
might synergize with HIV-1 by activating HIV-1 expres-mechanism of HIV-1 gene activation by EBV. In addition,
SupT1-CR2 may be a suitable cell system in which to sion in HIV-1 latently infected antigen-presenting cells,
such as monocytes or macrophages. Experiments areanalyze the early effects of HIV-1 and EBV coinfection.
U1.HIV-CR2 and J1.1-CR2 cell lines showed some ge- currently in progress in our laboratory to characterize
the mechanism of HIV-1 gene regulation by EBV in thenetic modifications after viral transduction, which, how-
ever, did not affect this study. HIV-1 was poorly induced cell culture systems we have described in this report,
to study the synergism in priming apoptosis in CD4/ Tby TNF-a treatment of U1.HIV-CR2 cells (Fig. 5B). The
supernatant of J1.1-CR2 cells has half the RT activity of cells by EBV and HIV-1 coinfection of monocyte-like
cells, and to establish whether the interaction betweenparental J1.1 cells (Fig. 5A). However, TNF-a treatment
of J1.1-CR2 cells restored HIV-1 RT activity in the super- the two viruses is somehow correlated to the multistep
process that leads to lymphomagenesis.natant to the same extent as that of J1.1 cells.
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FIG. 7. (A) RT assay of supernatants harvested from J1.1-CR2 and U1.HIV-CR2 cells (0.5 1 106 cells per point), after incubation with EBV of UV-
irradiated EBV. RT assay counts are indicated to the left of the panel. The various supernatants were tested by RT assay at two time points: t  0
and 4 hr. RT assay was carried out as described previously (Henderson et al., 1991). (B) RT assay of supernatants harvested from SupT1-CR2 cells
(0.5 1 106 cells per point) infected with HIV-1, with HIV-1 and EBV, or with HIV-1 and UV-irradiated EBV. SupT1-CR2 cells were incubated with HIV-
1, with HIV-1 and EBV, or with HIV-1 and UV-irradiated EBV as described (Henderson et al., 1991). At the end of the incubation time, cells were
washed and kept in culture for 72 hr, in 5 ml of RPMI-1640 supplemented with 10% fetal bovine serum and 2 mM L-glutamine. Supernatants were
harvested and tested in RT assay as described (Henderson et al., 1991).
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